International Clinical Trials Day marked
20 May 2015
Melinda Paton would not be alive today without MIA. Over three years ago, Melinda was told she had only nine months to live due to her stage four melanoma diagnosis. After being transferred to MIA she was placed on an Anti-PD-1 clinical trial.
"I started the Anti-PD-1 trial in September and by December 2013; my tumour had gone from the bowel. When I saw the scan, I was in complete disbelief; I couldn’t believe that it had just disappeared,” says Melinda.
“When I first met with Dr Georgina Long, as a stage 4 patient, the tumour was causing me a lot of pain and I was very weak. The tumours were progressing very quickly and I had surgery in December to have a lymph node removed. After this is when I went onto PD-1, where I noticed a difference almost immediately.
“With PD-1, I don’t have any pain, I’m not tired, and I don’t feel sick. I work full time and it lets me live as normal life as possible. The access to these drugs has been lifesaving, without them there is no doubt I would have died a long time ago.”
Melinda is benefiting from Anti-PD1 immunotherapy treatments and she is able to live as normal life as possible. It is thanks to dedicated clinicians that have discovered these clinical trials that are saving patients lives and improving cancer care globally.
There is still more work to be done. Donate now.
Little Madi misses her Dad. But she is determined to honour his memory and support life-saving melanoma research.
Toyota and country music fans invited to tip their hat to help tackle Australia's national cancer – melanoma
Melanoma Institute Australia has teamed up with the Toyota Country Music Festival 2018 in Tamworth!
MIA's dermatologist shares her knowledge with GPs on debunking myths and controversies on sunscreen.
Shannan Ponton thought he was invincible – he wasn’t. But his melanoma battle ended up saving more than his own life.
Researchers have demonstrated that immunotherapy is highly effective in treating a rare form of melanoma – a result that is surprising due to the nature of the tumour.
Innovation is helping to prevent melanoma developing in the first place.
Research from MIA is changing the way melanoma is managed worldwide and improving patient survival. Here are a few of our key highlights from this year.
A prestigious Fellowship has been awarded to fund research that will change the way melanoma treatment is assessed in the future.
New research from MIA has been published that forms the basis of the updated international guidelines for staging melanoma.
Professor William McCarthy AM has been awarded the Tom Reeve Award for Outstanding Contributions to Cancer Care.
Leading researchers from MIA have been acknowledged with three prestigious awards for excellence in melanoma research.
New research shows that patients who are more likely to respond to immunotherapy treatment have a greater diversity in their gut bacteria.
2018 will be bigger than ever, and a little bit different.
MIA's epidemiologist explains her new research on how country of residence should be considered when identifying melanoma risk.
Congratulations to our Conjoint Medical Directors, Professor Georgina Long and Professor Richard Scolyer, who have today been announced as Fellows of the Australian Academy of Health and Medical Sciences.
New research shows potentially deadly UV damage can appear decades earlier than you think.
Early lymph node check is saving lives in melanoma patients
We are pleased to announce that A/Prof Anne Cust is the new President of the Australasian Epidemiological Association.
More than $3.5 million in competitive funding grants have been awarded to MIA's researchers.